CURIS INC
CRISDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Dec 1, 2026
10wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How CRIS's past catalysts played out
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CURIS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in CURIS INC's (CRIS) pipeline across Phase 2. Its lead program is CUDC-907 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CURIS INC's next FDA catalyst?→
CURIS INC's (CRIS) next tracked catalyst is a Data Readout expected December 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRIS biotech catalysts?→
Add CRIS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CURIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.